183 related articles for article (PubMed ID: 30401377)
1. Intravenous Administration of Tacrolimus Stabilizes Control of Blood Concentration Regardless of CYP3A5 Polymorphism in Living Donor Liver Transplantation: Comparison of Intravenous Infusion and Oral Administration in Early Postoperative Period.
Kato H; Usui M; Muraki Y; Okuda M; Nakatani K; Hayasaki A; Ito T; Iizawa Y; Murata Y; Tanemura A; Kuriyama N; Azumi Y; Kishiwada M; Mizuno S; Sakurai H; Isaji S
Transplant Proc; 2018 Nov; 50(9):2684-2689. PubMed ID: 30401377
[TBL] [Abstract][Full Text] [Related]
2. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
[TBL] [Abstract][Full Text] [Related]
3. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
4. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
Wang L; Li N; Wang MX; Lu SC
Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
6. Influence of
Nakamura T; Fukuda M; Matsukane R; Suetsugu K; Harada N; Yoshizumi T; Egashira N; Mori M; Masuda S
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225074
[TBL] [Abstract][Full Text] [Related]
7. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
[TBL] [Abstract][Full Text] [Related]
8. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.
Uesugi M; Hosokawa M; Shinke H; Hashimoto E; Takahashi T; Kawai T; Matsubara K; Ogawa K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Biol Pharm Bull; 2013; 36(11):1814-21. PubMed ID: 24189425
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients.
Anutrakulchai S; Pongskul C; Kritmetapak K; Limwattananon C; Vannaprasaht S
Br J Clin Pharmacol; 2019 Sep; 85(9):1964-1973. PubMed ID: 31077425
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
13. [Effect of CYP3A4*18B, CYP3A5*3 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients].
Zhu L; Song HT; Wang QH; Wu WZ; Yang SL; Tan JM
Yao Xue Xue Bao; 2012 Jul; 47(7):878-83. PubMed ID: 22993851
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation.
Kato H; Usui M; Muraki Y; Tanemura A; Murata Y; Kuriyama N; Azumi Y; Kishiwada M; Mizuno S; Sakurai H; Okuda M; Nakatani K; Isaji S
Transplant Proc; 2016 May; 48(4):1087-94. PubMed ID: 27320564
[TBL] [Abstract][Full Text] [Related]
15. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms.
Miyata Y; Akamatsu N; Sugawara Y; Kaneko J; Yamamoto T; Suzuki H; Arita J; Sakamoto Y; Hasegawa K; Tamura S; Kokudo N
Ann Transplant; 2016 Aug; 21():491-9. PubMed ID: 27503662
[TBL] [Abstract][Full Text] [Related]
17. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
[TBL] [Abstract][Full Text] [Related]
18. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients.
Uesugi M; Masuda S; Katsura T; Oike F; Takada Y; Inui K
Pharmacogenet Genomics; 2006 Feb; 16(2):119-27. PubMed ID: 16424824
[TBL] [Abstract][Full Text] [Related]
19. The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation.
Wu Y; Fang F; Wang Z; Wen P; Fan J
Eur J Clin Pharmacol; 2021 Jun; 77(6):859-867. PubMed ID: 33386894
[TBL] [Abstract][Full Text] [Related]
20. Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation.
Fan B; Qiu K; Jiang Y; Hu X; Yin H; Wang W; Ren L; Liu H; Wang W; Zhang X
Biomed Pharmacother; 2017 Apr; 88():738-744. PubMed ID: 28157649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
